Myogen to Announce 2006 First Quarter Results on May 8, 2006
April 21 2006 - 7:00AM
Business Wire
Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on
the discovery, development and commercialization of small molecule
therapeutics for the treatment of cardiovascular disorders, today
announced that it will report 2006 first quarter results the
morning of Monday, May 8, 2006. J. William Freytag, President and
CEO, and other members of Myogen's senior management will provide a
company update and discuss results via webcast and conference call
on Monday, May 8, 2006, at 8:00 a.m. Eastern. To access the live
webcast, please log on to the company's website at www.myogen.com
and go to the Investor Relations section. Alternatively, callers
may participate in the conference call by dialing 800-240-2430
(domestic) or 303-205-0033 (international). Webcast and telephone
replays of the conference call will be available approximately two
hours after the completion of the call through Friday, May 26,
2006. Callers can access the replay by dialing 800-405-2236
(domestic) or 303-590-3000 (international). The passcode is
11058413#. About Myogen Myogen has two product candidates in
late-stage clinical development: ambrisentan for the treatment of
patients with pulmonary arterial hypertension (PAH) and darusentan
for the treatment of patients with resistant hypertension. Myogen
and GlaxoSmithKline have entered into a global PAH partnership in
which Myogen has marketing and distribution rights to
GlaxoSmithKline's Flolan (epoprostenol sodium) in the United States
for the treatment of PAH and GlaxoSmithKline has licensed
ambrisentan from Myogen for all territories outside of the United
States. Myogen also conducts a target and drug discovery research
program focused on the development of disease-modifying drugs for
the treatment of chronic heart failure and related cardiovascular
disorders. Please visit Myogen's website at www.myogen.com. Safe
Harbor Statement The 2006 first quarter results press release and
conference call will contain forward-looking statements that
involve significant risks and uncertainties, including those that
can be found in the "Risk Factors" section of Myogen's Form 10-K
for the year ended December 31, 2005 and in Myogen's periodic
reports on Form 10-Q and Form 8-K. Myogen is providing the
information contained in the release and conference call as of the
date of the release and does not undertake any obligation to update
any forward-looking statements as a result of new information,
future events or otherwise. The company cautions investors not to
place undue reliance on the forward-looking statements contained in
the press release or the conference call. No forward-looking
statement can be guaranteed and actual events and results may
differ materially from those projected.
Myogen (NASDAQ:MYOG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myogen (NASDAQ:MYOG)
Historical Stock Chart
From Sep 2023 to Sep 2024